News
REUN
1.120
0.00%
0.000
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
Reunion Neuroscience's lead asset, RE104, will be presented in a podium and poster at the Anxiety and Depression Association of America Conference in 2024. RE104 is a potential best-in-class, patented prodrug of a psilocybin-like compound. Reunion is evaluating RE104 in patients with postpartum depression.
Barchart · 04/03 06:30
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Benzinga · 08/14/2023 13:46
Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
Benzinga · 08/01/2023 19:43
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Benzinga · 07/24/2023 21:14
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Benzinga · 07/17/2023 21:04
'California Psilocybin Legalization Campaign Cleared To Collect Signatures For 2024 Ballot Initiative' - Marijuana Moment
Benzinga · 07/17/2023 15:13
Reunion Neuroscience shareholders approve acquisition by MPM BioImpact
Seeking Alpha · 07/13/2023 11:58
'Bipartisan Lawmakers Push For Marijuana And Psychedelics Amendments To Defense Bill, But Committee Action Is Delayed' - Marijuana Moment
Benzinga · 07/12/2023 15:45
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Benzinga · 06/29/2023 17:22
Reunion Neuroscience GAAP EPS of -C$0.56
Seeking Alpha · 06/29/2023 13:30
Recap: Reunion Neuroscience Q4 Earnings
Benzinga · 06/29/2023 12:25
Reunion Neuroscience: Q4 Earnings Insights
Benzinga · 06/29/2023 12:25
FDA Issues First Draft Guidance On Clinical Trials With Psychedelic Drugs
Benzinga · 06/23/2023 14:33
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Benzinga · 06/06/2023 14:57
What's Going On With Reunion Neuroscience Stock Today
Benzinga · 06/02/2023 14:26
Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
Benzinga · 06/01/2023 20:21
Reunion Neuroscience Explodes Higher on Buyout Deal
TipRanks · 06/01/2023 19:52
Nasdaq Surges Over 1%; Dollar General Lowers Annual Guidance
Benzinga · 06/01/2023 18:42
Why Victoria's Secret Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 06/01/2023 16:58
US Stocks Turn Higher; ISM Manufacturing PMI Drops In May
Benzinga · 06/01/2023 16:05
More
Webull provides a variety of real-time REUN stock news. You can receive the latest news about Reunion Neuroscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About REUN
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.